Home › Research Library › Peptide Research Library › Follistatin-344
Scientific Research Guide

Follistatin-344 (FS344) Reconstitution & BAC Water Research Guide

Follistatin-344 (FS344/FST344) is the longer precursor isoform of human follistatin, a protein that interacts with members of the TGF-β superfamily, including myostatin and activin. FS344 has been investigated extensively in preclinical muscle research and in experimental AAV-mediated gene-transfer studies, but it is not an FDA-approved drug product.

Direct answer: there is no scientifically established universal BAC-water volume for Follistatin-344. If a research vial contains a specified mass, the resulting concentration is determined mathematically by dividing that mass by the final liquid volume. The examples below are concentration calculations only — not clinical dosing or product reconstitution instructions.
Research Compound Not FDA Approved Human Evidence: Gene-Transfer Research
Scientific illustration of Follistatin-344 interacting with myostatin and activin signaling FOLLISTATIN-344 FS344 / FST344 research entity MYOSTATIN GDF-8 ACTIVIN TGF-β family FST344 RESEARCH BIOLOGY Simplified scientific illustration — not an exact molecular structure Follistatin can bind and antagonize several TGF-β-superfamily ligands.

Research Snapshot

Compound Follistatin-344
Class Follistatin protein isoform
Research Category Myostatin / activin biology
Regulatory Status Not FDA-approved
Human Evidence Experimental gene-transfer research
Vial Quantities No authoritative standard established

How Much BAC Water for Follistatin-344?

There is no single scientifically established BAC-water volume that applies to every Follistatin-344 research preparation. The appropriate liquid volume depends on the actual quantity of material in the vial and the target concentration required for a particular laboratory protocol.

Concentration = Total Vial Quantity ÷ Liquid Volume
Need a different vial quantity or liquid volume? Open BAC Water Calculator →

Calculate concentration mathematically using a custom vial quantity and liquid volume.

Vial Quantity 1 mL 2 mL 2.5 mL 3 mL 5 mL
5 mg 5 mg/mL 2.5 mg/mL 2 mg/mL 1.67 mg/mL 1 mg/mL
10 mg 10 mg/mL 5 mg/mL 4 mg/mL 3.33 mg/mL 2 mg/mL
Important: The 5 mg and 10 mg rows above are hypothetical mathematical examples. They do not establish that 5 mg or 10 mg are standardized commercial Follistatin-344 vial quantities, nor do they constitute instructions for preparing an injectable product.

How Much BAC Water Should Be Added to Follistatin-344?

Direct Research Answer

There is no authoritative universal BAC-water volume for Follistatin-344. The scientifically defensible calculation is to divide the total mass represented by the vial by the selected liquid volume to determine the resulting concentration.

For example, if a hypothetical vial contained 5 mg, 1 mL would mathematically produce 5 mg/mL, while 5 mL would mathematically produce 1 mg/mL. Those calculations describe concentration only; they do not establish a suitable formulation, route, dose, or human-use protocol.

How much BAC water for Follistatin-344 5 mg?

If a hypothetical research vial contains 5 mg, the mathematical concentration outcomes are:

  • 1 mL → 5 mg/mL
  • 2 mL → 2.5 mg/mL
  • 2.5 mL → 2 mg/mL
  • 3 mL → approximately 1.67 mg/mL
  • 5 mL → 1 mg/mL

These are concentration calculations, not recommendations for how much liquid should be introduced into a vial.

How much BAC water for Follistatin-344 10 mg?

If a hypothetical research vial contains 10 mg:

  • 1 mL → 10 mg/mL
  • 2 mL → 5 mg/mL
  • 2.5 mL → 4 mg/mL
  • 3 mL → approximately 3.33 mg/mL
  • 5 mL → 2 mg/mL

How does BAC-water volume change Follistatin-344 concentration?

With the same total amount of protein, increasing the liquid volume lowers the concentration, while decreasing the liquid volume raises the concentration. The total mass represented by the vial does not change simply because the liquid volume changes.

How do you calculate Follistatin-344 concentration?

1 Identify vial quantity

Use the actual quantity stated on the vial, COA, or authoritative product documentation.

2 Identify liquid volume

Use the volume specified by the applicable laboratory or product-specific protocol.

3 Divide mass by volume

Concentration in mg/mL = mg of material ÷ mL of liquid.

What Is Follistatin-344?

Follistatin is a secreted glycoprotein encoded by the human FST gene. Alternative splicing produces different follistatin isoforms. FST344 is the longer precursor form containing 344 amino acids; after removal of its signal peptide, the corresponding mature long isoform is commonly referred to as FS315.

Follistatin is biologically important because it binds members of the transforming growth factor-beta (TGF-β) superfamily. Research has particularly focused on its interaction with myostatin (GDF-8) and activin, signaling molecules involved in muscle biology and other physiological processes.

NCBI records FST344 as a human follistatin transcript/protein isoform, while structural research has characterized how follistatin domains contribute to ligand antagonism.

Simplified Follistatin-344 myostatin and activin signaling diagram Simplified Follistatin Signaling Model FOLLISTATIN-344 FS344 / FST344 ligand-binding protein MYOSTATIN GDF-8 ACTIVIN TGF-β superfamily ↓ TGF-β pathway downstream signaling and muscle biology Simplified research schematic; ligand interactions are more complex than depicted and are not to scale.
Research visual: simplified representation of follistatin interaction with TGF-β-superfamily signaling. It is not an exact molecular structure or complete signaling pathway.

How Follistatin-344 Works

Follistatin acts primarily as an extracellular ligand-binding protein. Its follistatin domains can bind and neutralize signaling molecules from the TGF-β superfamily. Research has demonstrated interactions involving activin and myostatin, although the binding characteristics differ among ligands and follistatin domains.

Myostatin is a negative regulator of skeletal-muscle growth. Experimental studies therefore investigated whether increasing follistatin activity could alter myostatin signaling and muscle phenotype. Research also indicates that activin antagonism contributes to some follistatin-associated effects.

Target
Myostatin / GDF-8

A major negative regulator of skeletal-muscle growth investigated in follistatin research.

Target
Activin

A TGF-β-superfamily ligand that is also antagonized by follistatin.

Research Model
FS344 Gene Transfer

AAV-mediated expression has been studied in animal models and experimental human gene-transfer trials.

What Is Follistatin-344 Being Studied For?

Follistatin-related research has focused heavily on the regulation of skeletal-muscle growth and the possibility of modifying myostatin signaling. Preclinical studies have examined muscle hypertrophy, muscle strength and muscular dystrophy models.

Experimental human studies involving FS344 have primarily used gene-transfer approaches rather than conventional administration of purified Follistatin-344 protein. The registered clinical studies included Becker muscular dystrophy, sporadic inclusion body myositis and Duchenne muscular dystrophy.

Human Clinical Research

Important distinction

Human research involving FS344 does exist, but the studies identified here are gene-transfer studies. They should not be interpreted as clinical studies of a standard reconstituted Follistatin-344 vial.

In NCT01519349, investigators studied intramuscular delivery of an AAV vector carrying the human follistatin-344 gene in Becker muscular dystrophy and sporadic inclusion body myositis. NCT02354781 similarly studied rAAV1.CMV.huFollistatin344 in Duchenne muscular dystrophy.

Doses Studied in Published Research

The following table summarizes experimental human gene-transfer studies. These are research protocol parameters, not BacScience dosage recommendations.

Study Population Dose Studied Route Frequency Duration / Follow-up Research Focus
NCT01519349 BMD / sIBM 2E11 vg/kg;
3E11 vg/kg/quad;
6E11 vg/kg/quad 		Intramuscular AAV gene transfer Single gene-transfer administration Up to 2 years Safety, muscle size and function
NCT02354781 DMD 2.4E12 vg/kg total Multiple intramuscular sites Single administration Up to 24 months Safety and functional outcomes
These were gene-therapy vector doses, not Follistatin-344 protein doses.

Viral-vector genome copies (vg/kg) cannot be converted into mg/mL protein concentration and should not be used as a reconstitution calculation for a Follistatin-344 vial.

Preclinical Research

The preclinical literature is substantially broader than the human clinical literature. Experimental follistatin overexpression has been associated with increased skeletal-muscle mass in animal models.

In one mouse study, follistatin overexpression increased muscle weight, and experiments using a follistatin mutant suggested that inhibition of both myostatin and activin contributed to the observed hypertrophy.

Separate work involving transgenic pigs expressing human follistatin-344 reported increased skeletal-muscle proportion and myofiber hypertrophy. These findings are useful for understanding biological mechanisms but do not establish efficacy or safety in humans.

Research Reconstitution & Concentration

The core mathematical relationship is:

Concentration (mg/mL) = Total vial quantity (mg) ÷ Liquid volume (mL)

Worked example: hypothetical 5 mg vial

If a hypothetical vial contained exactly 5 mg of material, then:

  • 5 mg ÷ 1 mL = 5 mg/mL
  • 5 mg ÷ 2 mL = 2.5 mg/mL
  • 5 mg ÷ 2.5 mL = 2 mg/mL
  • 5 mg ÷ 5 mL = 1 mg/mL

Worked example: hypothetical 10 mg vial

If a hypothetical vial contained exactly 10 mg:

  • 10 mg ÷ 1 mL = 10 mg/mL
  • 10 mg ÷ 2 mL = 5 mg/mL
  • 10 mg ÷ 2.5 mL = 4 mg/mL
  • 10 mg ÷ 5 mL = 2 mg/mL

These examples demonstrate arithmetic only. They do not establish that any of these volumes are suitable for a specific Follistatin-344 formulation.

BAC Water vs. Follistatin-344 Concentration

BAC water is a type of bacteriostatic diluent. However, the existence of a mathematical concentration relationship does not mean that BAC water is universally appropriate for every protein preparation.

For Follistatin-344 specifically, the authoritative human studies identified for this page used viral gene-transfer systems rather than a conventional BAC-water reconstitution protocol.

Concentration principle

More liquid → lower concentration.
Less liquid → higher concentration.
Total vial mass remains mathematically unchanged.

Researchers should therefore distinguish between the mathematical concentration of a solution and the validated formulation, stability, sterility, compatibility and handling requirements of a specific protein preparation.

Research Limitations & Safety

Follistatin-344 is not an FDA-approved human drug product. FDA records show orphan-drug designations for adeno-associated-virus-delivered follistatin transgene products in inclusion body myositis and Duchenne and Becker muscular dystrophy, but the FDA database explicitly lists those products as not FDA approved for the orphan indications.

FDA has also previously cited follistatin among substances used in compounded drug products that did not meet the applicable conditions for the 503A exemptions described in the cited warning letter. That regulatory history should not be interpreted as an approval or validation of commercially available Follistatin-344 preparations.

An additional quality concern is product identity. Published analytical work examining black-market products labeled Follistatin-344 found substantial product-quality problems: only 9 of 17 tested products contained follistatin, and several products contained other growth- promoting peptides. This is one reason analytical identity, purity and batch documentation matter when interpreting research material.

Research-only interpretation

Follistatin-344 research findings should not be interpreted as proof that an unapproved commercial preparation is safe, sterile, pure, clinically effective or suitable for human administration.

Concentration, Research Dose and Clinical Dose Are Different

One of the most important concepts on this page is that these terms are not interchangeable:

  • Mathematical concentration: mass divided by liquid volume.
  • Research protocol dose: the quantity specified within a particular experimental study.
  • Clinical dose: a dose established within an appropriate human clinical context.
  • FDA-approved dosage: a dosing instruction associated with an FDA-approved product and indication.
  • Community protocol: an informal practice that does not establish clinical safety or efficacy.

For Follistatin-344, the human studies discussed above involved experimental AAV gene transfer. They do not establish a conventional human dose of reconstituted Follistatin-344 protein.

Frequently Asked Questions About Follistatin-344 Reconstitution

How much BAC water should be added to Follistatin-344?
No universal scientifically established BAC-water volume was identified for Follistatin-344. The resulting concentration is calculated from the actual material quantity and liquid volume. A product-specific validated formulation, if applicable, takes precedence over generic mathematical examples.
How much BAC water for a hypothetical 5 mg Follistatin-344 vial?
Mathematically, 5 mg in 1 mL equals 5 mg/mL; 2 mL equals 2.5 mg/mL; 2.5 mL equals 2 mg/mL; and 5 mL equals 1 mg/mL. These are mathematical examples only and do not establish a recommended preparation.
How much BAC water for a hypothetical 10 mg Follistatin-344 vial?
Mathematically, 10 mg in 1 mL equals 10 mg/mL; 2 mL equals 5 mg/mL; 2.5 mL equals 4 mg/mL; and 5 mL equals 2 mg/mL. These values describe concentration only.
What is the Follistatin-344 concentration formula?
Concentration in mg/mL equals total material quantity in mg divided by liquid volume in mL.
Does adding more BAC water lower Follistatin-344 concentration?
Yes. Assuming the same total quantity of material, increasing liquid volume lowers the resulting concentration.
Is Follistatin-344 FDA approved?
No FDA-approved Follistatin-344 drug product or FDA-approved Follistatin-344 dosage was identified for the research context described on this page. FDA records list orphan designations for follistatin gene-transfer products but identify those products as not FDA approved for the designated indications.
Has Follistatin-344 been studied in humans?
Yes, but the important distinction is that identified human studies used AAV-mediated gene transfer of the human follistatin 344 gene. These studies should not be treated as clinical trials of conventional reconstituted Follistatin-344 protein.
Is Follistatin-344 the same as generic follistatin?
Follistatin is a protein family with different isoforms. FST344 refers specifically to the longer 344-amino-acid precursor transcript/protein form. Alternative processing produces the mature long circulating FS315 form.
What is Follistatin-344 being researched for?
Research has focused strongly on myostatin and activin biology, skeletal-muscle growth, muscle-wasting disorders and gene-transfer approaches. Most mechanistic evidence remains preclinical, while human research has included experimental gene-transfer studies.
Can the Follistatin-344 clinical trial dose be converted into mg/mL?
No. The clinical trials discussed here used AAV vector genome quantities such as vg/kg. Viral-vector dose is a fundamentally different measurement from the mg/mL concentration of a purified protein solution.
Does BacScience recommend a human Follistatin-344 dose?
No. BacScience's research content should not be interpreted as prescribing or recommending human treatment. This page provides scientific background and mathematical concentration examples.

Scientific References

  1. NCBI RefSeq — Homo sapiens follistatin FST344. Reference information for the human FST344 transcript/protein isoform.
    NCBI FST344 Reference Sequence
  2. NCBI Protein — Follistatin isoform FST344 precursor. Human protein reference record and structural information.
    NCBI NP_037541.1
  3. Cash et al., Molecular Endocrinology. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism. PMID: 22593183.
    PubMed
  4. Gilson et al., American Journal of Physiology. Follistatin-induced muscle hypertrophy and the contribution of myostatin and activin inhibition. PMID: 19435857.
    PubMed
  5. Rodino-Klapac et al., Muscle & Nerve. Review of myostatin inhibition and follistatin-based approaches for muscle disease. PMID: 19208403.
    PubMed
  6. Chang et al., Transgenic Research. Transgenic expression of human follistatin-344 and skeletal-muscle phenotype in pigs. PMID: 27787698.
    PubMed
  7. ClinicalTrials.gov — NCT01519349. Follistatin gene transfer to patients with Becker muscular dystrophy and sporadic inclusion body myositis.
    ClinicalTrials.gov
  8. ClinicalTrials.gov — NCT02354781. Phase I/II clinical intramuscular gene transfer of rAAV1.CMV.huFollistatin344 in Duchenne muscular dystrophy.
    ClinicalTrials.gov
  9. FDA Orphan Drug Database. Adeno-associated-virus-delivered follistatin transgene for inclusion body myositis; designation listed as not FDA approved.
    FDA Orphan Drug Record
  10. FDA Orphan Drug Database. Adeno-associated-virus follistatin transgene for Duchenne and Becker muscular dystrophy; designation listed as not FDA approved.
    FDA Orphan Drug Record
  11. Follistatin-344 analytical detection study. Published analysis of products labeled as black-market Follistatin-344. PMID: 31758732.
    PubMed

Explore More BacScience Research Resources

⌘
BAC Water Calculator Calculate concentration using custom vial quantities and liquid volumes.
▦
Research Compound Library Replace this link with the live BacScience research compound library URL.
◈
Peptide Research Library Replace this link with the live peptide research library URL.
✓
Testing & Transparency Replace this link with BacScience's testing and transparency resource page.
Last Scientifically Reviewed

September 10, 2026

Scientific review: BacScience Research Editorial Team
Medical/scientific reviewer: [INSERT QUALIFIED REVIEWER NAME / CREDENTIALS]

Educational and research information only

This page is intended to explain scientific literature, concentration mathematics and research terminology. It does not provide medical treatment advice, establish a human dose, establish an FDA-approved use, validate a commercial product, or recommend a particular reconstitution procedure. Always distinguish experimental research parameters from validated pharmaceutical instructions.